Radiopharmaceutical company Fusion Pharmaceuticals Inc. is acquiring a phase II actinium-based alpha-emitter radiopharma program for prostate cancer from Radiomedix Inc.
Indicating its continuing strategy to invest in antibody-drug conjugates (ADCs), Astrazeneca plc obtained exclusive global rights to Claudin 18.2 ADC CMG-901 from Keymed Biosciences Inc. and Lepu Biopharma Co. Ltd. in a deal worth up to $1.163 billion.
Transthera Sciences Inc., a Nanjing, China-based company developing small-molecule therapies in cancer, inflammation and cardiovascular disease, raised ¥260 million (US$38 million) in a series D+ funding round to advance its first drug product.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have discovered fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.
Beijing Tide Pharmaceutical Co. Ltd. proteolysis-targeting chimera (PROTAC) compounds comprising a ubiquitin ligase-binding moiety bonded to a protein phosphatase nonreceptor type 11 (PTPN11)-targeting moiety through a linker.
Squamous cell carcinoma (SCC) consists of heterogeneous tumors that originate from surface epithelial cells, with a dynamic keratinocyte (KC)-specific network of epigenetic modifications and transcription factors (TFs) being involved in squamous cell fate determination and oncogenesis. In recently published work, researchers from Massachusetts General Hospital and affiliated organizations aimed to identify kinases that control these processes and could therefore have therapeutic applications.
For Aqemia SA, the year got off to a good start, as one of its pharma partners, Les Laboratoires Servier SAS, extended an existing collaboration to drug a supposedly undruggable immuno-oncology target, using its Launchpad artificial intelligence platform.
RSS
